Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates

Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates

  • Acquisition will add another key dimension to Boehringer Ingelheim’s focus on patients with difficult-to-treat solid tumors
  • NBE-Therapeutics’ pipeline is based on its innovative next generation antibody-drug conjugate (ADC) technology platform
  • NBE-Therapeutics’ will remain at its campus in Basel, Switzerland and operate as a new site within Boehringer Ingelheim’s R&D network

Ingelheim, Germany and Basel, Switzerland – 10 December 2020 – Boehringer Ingelheim today announced the signing of a binding agreement for acquiring all shares of NBE-Therapeutics, a private, clinical-stage Swiss biotechnology company focused on antibody-drug conjugates and advancing targeted cancer therapies derived from its immune stimulatory iADC™ platform. NBE-Therapeutics’ lead compound NBE-002 is currently in phase I clinical studies for triple negative breast cancer and other solid tumors. Importantly, Boehringer Ingelheim gains access to an innovative and unique platform that it will use to build a leading ADC portfolio and develop potential combinations with other assets from its cancer immunology portfolio.

Read more

 

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH